Clinical Trial Update: Cystatin c: a Biomarker of AKI in Aneurysmal Subarachnoid Haemorrhage Patients

View source ↗

Summary

This completed clinical trial evaluated cystatin C as a biomarker for acute kidney injury in patients with aneurysmal subarachnoid hemorrhage.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aneurysmal Subarachnoid Hemorrhage
• Kidney Injury

Snippet

Sponsor: Alexandria University | Conditions: Acute Kidney Injury | Status: COMPLETED